In 31 previously infected children aged 5–11 (trial stopped early), one dose of BNT162b2 gave similar day-28 neutralising antibody titres to two doses (GMR 0.9; 95% CI 0.5–1.6), but non-inferiority could not be shown as the trial was underpowered.
RCTn = 31
Prat-Aymerich et al. A prematurely terminated phase 2, randomised trial to evaluate immunogenicity and reactogenicity of a single versus two-dose primary vaccination regimen of the mRNA vaccine BNT162b2 in previously SARS-CoV-2 infected children 5-11 years old (CoVacc trial)